Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

iBio, Inc. (IBIO)

1.29   -0.08 (-5.84%) 02-08 09:35
Open: 0.9545 Pre. Close: 1.37
High: 1.31 Low: 1.26
Volume: 205,495 Market Cap: 14(M)

Technical analysis

as of: 2023-02-07 4:29:11 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.74     One year: 2.03
Support: Support1: 0.85    Support2: 0.46
Resistance: Resistance1: 1.49    Resistance2: 1.74
Pivot: 0.78
Moving Average: MA(5): 0.9     MA(20): 0.77
MA(100): 2.19     MA(250): 5.36
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 57.4     %D(3): 45.5
RSI: RSI(14): 78.3
52-week: High: 16.5  Low: 0.23
Average Vol(K): 3-Month: 783 (K)  10-Days: 1,571 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IBIO ] has closed above the upper band by 38.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.49 - 1.5 1.5 - 1.5
Low: 0.87 - 0.88 0.88 - 0.88
Close: 1.36 - 1.37 1.37 - 1.38

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Headline News

Wed, 08 Feb 2023
Current and Future Analysis of Yellow Fever Treatment Market With New Business Strategies and Forecast by 2030 - openPR

Wed, 08 Feb 2023
A glimpse at iBio Inc.'s potential climb to old highs - The Dwinnex

Tue, 07 Feb 2023
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch

Tue, 07 Feb 2023
Healthcare Stocks on the Move Tuesday: KPRX, IBIO, CYAD, OSH, CHEK, REVB, CVAC, MYMD - InvestorsObserver

Tue, 07 Feb 2023
Should You Buy Ibio Inc (IBIO) Stock Tuesday? - InvestorsObserver

Mon, 06 Feb 2023
Plant-based Vaccines Market is Booming Worldwide | Mitsubishi ... - Digital Journal

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 218 (M)
% Held by Insiders 2.167e+008 (%)
% Held by Institutions 1.2 (%)
Shares Short 11,600 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.038e+007
EPS Est Next Qtl 0
EPS Est This Year -0.16
EPS Est Next Year -0.21
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 520.1
Return on Equity (ttm) -15.9
Qtrly Rev. Growth 2.17e+006
Gross Profit (p.s.) 0.01
Sales Per Share 0
EBITDA (p.s.) -0.08
Qtrly Earnings Growth -0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -32 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 182.4
Price to Cash Flow -16.92

Stock Dividends

Dividend 0
Forward Dividend 1.117e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.